In a significant announcement at the 2025 ASCO Annual Meeting, OnCusp Therapeutics unveiled the Phase 1a results of their groundbreaking drug, CUSP06. This CDH6-Directed Antibody-Drug Conjugate (ADC) has shown encouraging signs of efficacy in the treatment of platinum-refractory/resistant ovarian cancer and other advanced solid tumors. This revelation signals a potential paradigm shift in the ongoing battle against these resilient forms of cancer.
Data from the Phase 1a trial, which included 37 patients who had previously undergone heavy treatment, indicated a laudable 36% overall response rate in platinum-resistant High-Grade Serous Ovarian Cancer (HGSOC), a notoriously difficult form of cancer to treat. This level of efficacy was observed regardless of CDH6 pre-selection, suggesting the drug’s broad spectrum of activity.
What’s more, a clinical benefit rate of 92% was observed, a figure that far surpasses many established treatments in the field. Furthermore, CA-125 responses were seen in 45% of evaluable HGSOC patients, a significant marker of the disease’s progression.
CUSP06’s safety profile is equally compelling. The most common treatment-related adverse events were manageable hematologic toxicities, marking a departure from the severe side effects often associated with cancer treatments.
What sets CUSP06 apart is its differentiated profile and potentially best-in-class activity. As a CDH6-directed ADC, it is consistent with other TOP1-inhibitor ADCs, yet its results suggest it may be a game-changer.
The CEO of OnCusp Therapeutics, Dr. Bing Yuan, expressed excitement at these early results. He emphasized both the promising activity in platinum-resistant HGSOC and the fact that this was achieved without requiring CDH6 biomarker selection. This, combined with previously presented preclinical findings, underscores the best-in-class potential of CUSP06.
The Phase 1a results have provided the impetus for further exploration of CUSP06 in Phase 1b expansion cohorts for platinum-resistant HGSOC and other CDH6-positive tumors. The primary objective of this first-in-human study is to assess safety, tolerability, pharmacokinetics, and preliminary efficacy, with the Phase 1b portion further characterizing safety and efficacy in select tumor types.
OnCusp’s announcement underscores a broader trend in the biotech industry: the move towards precision therapeutics and an individualized approach to cancer treatment. By leveraging cutting-edge bioengineering techniques and a deep understanding of tumor biology, OnCusp is at the forefront of harnessing the body’s own immune system to fight cancer.
There are still many battles to be won in the war against cancer, but with the advent of therapies like CUSP06, we are armed with increasingly effective weapons. The results from OnCusp Therapeutics provide a glimmer of hope for patients with platinum-resistant HGSOC and other advanced solid tumors, and offer a tantalizing glimpse into the future of personalized cancer treatment.
Read more from seekingalpha.com
